Significant Ownership of Bellevue Group AG
- Signature - Title
- /s/ Stefano Montalbano - Stefano Montalbano/ Chief Financial Officer
- Location
- Zurich
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by Bellevue Group AG.
Follow Filing Activity
Follow Bellevue Group AG and return when a new Schedule 13D/G filing appears.
This tracks SEC filing changes for this page using existing product update flows.
Continue schedule research
Related filing hubs for this reporting manager, useful for reinforcing crawl paths across the schedule cluster.
Significant Ownership of Bellevue Group AG
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| JBIO | Jade Biosciences, Inc. | Common Stock | 6.8% | $46,307,688 | 3,341,103 | Bellevue Group AG | 16 Dec 2025 | ||
| IMCR | Immunocore Holdings plc | Ordinary shares | 5.6% | $101,607,853 | 2,796,803 | Bellevue Group AG | 20 Aug 2025 | ||
| CLDX | Celldex Therapeutics, Inc. | Common Stock | 5.4% | $93,589,097 | 3,617,669 | Bellevue Group AG | 18 Aug 2025 | ||
| MGNX | MacroGenics, Inc. | Common Stock | 0% | $0 | -$13,901,948 | 0 | -100% | Bellevue Group AG | 05 Dec 2025 |
| AGIO | Agios Pharmaceuticals, Inc. | Common Stock | 0% | $0 | -$142,398,726 | 0 | -100% | Bellevue Group AG | 19 Nov 2025 |
Schedules 13D/G Reported by Bellevue Group AG:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.